David Glenn reported acquisition or exercise transactions in a Form 4 filing for PAHC. The filing lists transactions totaling 72,528 shares at a weighted average price of $51.63 per share. Following the reported transactions, holdings were 240,000 shares.
A shareholder of PAHC has filed a notice of proposed sale under Rule 144 for 12,528 Class A shares. The planned sale, through Fidelity Brokerage Services LLC on the NASDAQ, has an aggregate market value of $646,757.50 based on the figures provided.
The shares were acquired on 02/10/2026 via restricted stock vesting from the issuer as compensation, with payment on the same date. The filing notes that 20,623,682 shares of this class were outstanding and lists an approximate sale date of 02/11/2026.
Barclays PLC reported a passive ownership stake in Phibro Animal Health Corp-A common stock on a Schedule 13G. Barclays beneficially owns 1,042,888 shares, representing 5.10% of the class, with sole voting and sole dispositive power over all reported shares as of December 31, 2025.
Barclays states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Phibro Animal Health. Subsidiaries involved include Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.
Phibro Animal Health Corp’s insider filing shows activity on February 5, 2026 involving an entity associated with President and CEO Jack Bendheim. BFI Co., LLC converted 185,000 shares of Class B Common Stock into 185,000 shares of Class A Common Stock at an exercise price of $0.
BFI then executed several open-market sales of Class A shares under a Rule 10b5-1 trading plan, with individual trades ranging from 409 to 46,275 shares at weighted average prices between $44.4688 and $49.5718. After these transactions, BFI indirectly held 122,958 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health insider activity shows trades by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim and a 10% owner. On February 4, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A on a one-for-one basis at $0 per share.
BFI then sold Class A shares in several transactions: 6,689 shares at $41.2508, 2,971 shares at $41.9667, and 3,520 shares at $41.1544, all reported as weighted average prices under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these trades, BFI held 48,800 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares and BFI continued to hold additional Class B shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.
Phibro Animal Health Corporation filed a Form 8-K stating that on February 4, 2026 it issued a press release announcing operating results for the fiscal quarter ended December 31, 2025 and financial guidance for the fiscal year ending June 30, 2026. The press release is furnished as Exhibit 99.1 and, along with the 8-K disclosure, is designated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Phibro Animal Health Corporation reported sharply stronger results. For the quarter ended December 31, 2025, net sales reached $373.9 million, up 21% from $309.3 million. Net income rose to $27.5 million from $3.2 million, with basic earnings per share increasing to $0.68 from $0.08.
Growth was led by the Animal Health segment, helped by the October 2024 acquisition of Zoetis’s medicated feed additive and water-soluble products portfolio. This portfolio contributed $94.1 million of quarterly revenue and $174.6 million over six months. Six‑month net sales grew 30% to $737.8 million, while net income climbed to $54.0 million from $10.2 million.
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend will be paid on March 25, 2026 to stockholders who are on record as of the close of business on March 4, 2026.
This cash dividend provides shareholders with a direct cash return based on the number of shares they hold on the record date.
Phibro Animal Health (PAHC) insider activity centers on planned sales by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI sold 6,772 Class A Common shares at a weighted average price of $40.1192 on January 29, 2026, and 6,693 shares at $40.0941 on January 30, 2026, under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these transactions, BFI held 38,673 and then 31,980 shares indirectly, while Bendheim also directly held 16,840 Class A Common shares.
Phibro Animal Health insider activity shows trades by major shareholder BFI Co., LLC, an entity over which President and CEO Jack Bendheim has voting and dispositive power. On January 23, 2026, BFI sold 1,235 shares of Class A Common Stock at a weighted average price of $40.5538 per share under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 26, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A Common Stock on a one-for-one basis at an exercise price of $0. Following these transactions, BFI indirectly held 45,445 Class A shares, while Jack Bendheim also directly held 16,840 Class A shares.